Full Press Release Details
Just - Evotec Biologics Receives
Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Hamburg, Germany, January 08,
Evotec SE (NASDAQ: EVO; Frankfurt Prime
Standard: EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant
from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design
suite of computational technologies, called "J.MD ".
Investment (INV072135) continues the
support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to
make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.
Under the grant terms, Just -
Evotec Biologics will leverage its J.MD Molecular Design service - a key component of its J.DESIGN platform, that integrates
advanced computational tools and high-throughput methodologies to streamline the biologics development process. By optimizing molecular
design from the earliest stages, J.MD ensures manufacturability, stability, and efficacy-critical factors for reducing costs
and enabling expansion of global access to these therapies as well as limiting liabilities like immunogenicity and instability. The new
investment will enable ten (10) new J.MD projects over the next three years, spanning the development of biotherapeutics
targeting multiple global health disease indications of concern.
This grant extends the commitment of
Just - Evotec Biologics, that began in 2014 and has since delivered multiple cGMP manufacturing campaigns for RSV, Malaria, and
HIV monoclonal antibodies.
Zuckerman, EVP and Global Head of Just - Evotec Biologics, commented: "We are thrilled to receive this new grant from
the Gates Foundation which will strengthen our commitment to reducing the cost of biologics development to expand global access. By leveraging
our J.DESIGN platform and innovative molecular design tools, we look forward
to supporting the foundation in driving impactful solutions across multiple disease areas and continuing to deliver therapies where they
Dr. Cord Dohrmann, Chief Scientific
Officer of Evotec, added: "We are proud to continue our collaboration with the foundation through this new grant which enables
us to harness Just - Evotec Biologics' advanced platforms and scientific expertise to support the broader research ecosystem.
This partnership strengthens our shared mission to accelerate the development of biotherapeutics that address urgent and unmet medical
For expert insights about the importance
of thoughtful antibody design driving global access, watch our virtual roundtable, Antibody Design to Support Global Health Initiatives,
featuring key voices from the Gates Foundation and global health researchers.
About Just - Evotec Biologics
Just - Evotec Biologics, wholly
owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design,
cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through
clinical stages to commercial launch. The Just - Evotec Biologics team combines deep industry experience in the fields of data,
protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the
scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access
to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn
more at www.just-evotecbiologics.com.
Evotec is a life science company
that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced
technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules,
biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics
and iPSC-based disease modeling.
With flexible partnering models tailored
to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders.
Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific
excellence with operational agility.
Through Just - Evotec Biologics,
we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100
proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic
diseases, neurology, and immunology.
Evotec's global team of more
than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers
Forward-looking statements
This announcement contains forward-looking
statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "might,"
"plan," "potential," "should," "target," "would" and variations of such words
and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's
expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can
be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon
a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are
beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change
in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations and Media Contact
EVP Head of Global Communications &